Jyoti D Patel

Professor, Medicine, Hematology Oncology Division

Phone+1 312 695 4549
Emailjd-patel@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Certifications and Licenses

Medical Oncology

Training Experience

1999	Residency, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)
2003	Fellowship, Memorial Sloan-Kettering Cancer Center

Education/Academic qualification

Medicine, MD, Indiana University

… → 1996

MD, Indiana University Bloomington

… → 1996

Research interests

Lung Cancer

Fingerprint

Dive into the research topics where Jyoti D Patel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

11 Active
39 Finished

Prot #VS-6766-202: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)
Patel, J. D.
Parexel, Verastem, Inc.
5/21/21 → 5/21/24
Project: Research project
Prot #AFT-46: CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Patel, J. D.
Alliance Foundation Trials, LLC, AstraZeneca Pharmaceuticals LP
4/21/21 → 4/21/24
Project: Research project
Prot #U31402-A-U201: HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Patel, J. D.
INC Research, LLC, Daiichi Sankyo, Inc.
4/9/21 → 4/9/24
Project: Research project
Prot #20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Patel, J. D.
Greenphire, Inc., Amgen, Inc.
2/23/21 → 2/23/24
Project: Research project
Prot #HCRN LUN18-335/NU MDA20L01: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Patel, J. D.
Hoosier Cancer Research Network, Inc., Lilly USA, LLC
1/14/21 → 1/14/24
Project: Research project

5167 Citations
50 Article
28 Review article
2 Comment/debate
1 Letter
More
- 1 Short survey

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Khaddour, K., Gomez-Perez, S. L., Jain, N., Patel, J. D. & Boumber, Y., Oct 20 2020, In: Frontiers in Oncology. 10, 576314.
Research output: Contribution to journal › Review article › peer-review

Open Access
1 Scopus citations
A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence
Schnoll, R., Leone, F., Veluz-Wilkins, A., Miele, A., Hole, A., Jao, N. C., Paul Wileyto, E., Carroll, A. J., Kalhan, R., Patel, J., Langer, C., Lubitz, S. F. & Hitsman, B., Mar 2019, In: Psycho-oncology. 28, 3, p. 561-569 9 p.
Research output: Contribution to journal › Article › peer-review
9 Scopus citations
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Gadgeel, S. M., Lukas, R. V., Goldschmidt, J., Conkling, P., Park, K., Cortinovis, D., de Marinis, F., Rittmeyer, A., Patel, J. D., von Pawel, J., O'Hear, C., Lai, C., Hu, S., Ballinger, M., Sandler, A., Gandhi, M. & Fehrenbacher, L., Feb 2019, In: Lung Cancer. 128, p. 105-112 8 p.
Research output: Contribution to journal › Article › peer-review
45 Scopus citations
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center
Choudhury, N. J., Eghtesad, M., Kadri, S., Cursio, J., Ritterhouse, L., Segal, J., Husain, A. & Patel, J. D., Oct 1 2019, In: Oncotarget. 10, 56, p. 5817-5823 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J. & Giles, F., Jan 1 2017, In: Cancer Immunology, Immunotherapy. 66, 1, p. 25-32 8 p.
Research output: Contribution to journal › Article › peer-review
62 Scopus citations